Mesbro 600mg Injection

Introduction

Mesbro is a medication that contains the active ingredient Mesna. It is available in the form of an injection and is primarily used in the treatment and prevention of certain side effects associated with chemotherapy drugs.

Uses

Mesbro is prescribed to patients undergoing chemotherapy for the treatment of cancer. It helps to protect the bladder from the harmful effects of certain chemotherapy medications, such as ifosfamide and cyclophosphamide.

Dosage and Administration

The dosage of Mesbro may vary depending on the specific chemotherapy regimen being used and the patient’s individual needs. It is typically administered as an intravenous infusion or injection. The healthcare provider will determine the appropriate dosage and method of administration based on the patient’s condition.

Mechanism of Action

Mesna, the active ingredient in Mesbro, works by binding to and neutralizing the harmful byproducts of certain chemotherapy drugs. This helps to prevent damage to the bladder and reduce the risk of side effects such as hemorrhagic cystitis.

Side Effects

Common side effects may include nausea, vomiting, diarrhea, headache, and dizziness. Notify your healthcare provider if these side effects persist or worsen.

Serious side effects are rare but can occur. These may include signs of an allergic reaction (such as rash, itching, swelling, severe dizziness, or difficulty breathing) and signs of a bladder infection (such as pain or burning during urination, frequent urination, or blood in the urine). If you experience any of these serious side effects, seek immediate medical attention.

Drug Interactions

Mesbro may interact with certain medications, potentially affecting their effectiveness or increasing the risk of side effects. Inform your healthcare provider about all the medications you are taking, including prescription drugs, over-the-counter medications, and herbal supplements.

Some medications that may interact with Mesbro include ifosfamide and cyclophosphamide, as well as certain blood thinners. Your healthcare provider will monitor your treatment closely and adjust the dosage or medication regimen as needed to minimize the risk of interactions.

Precautions

Before using Mesbro, inform your healthcare provider about any medical conditions you have, especially if you have a history of kidney problems or urinary tract disorders. Additionally, let your healthcare provider know if you are pregnant, planning to become pregnant, or breastfeeding.

Mesbro should not be used in patients who are allergic to Mesna or any other ingredients in the medication. Follow your healthcare provider’s instructions and any additional precautions they may provide to ensure safe and effective use of this medication.

Storage

Patient Tips

• Follow your healthcare provider’s instructions regarding the administration of Mesbro.
• If you miss a dose, contact your healthcare provider for guidance.
• Stay well hydrated during chemotherapy treatment to help reduce the risk of bladder-related side effects.
• Report any new or worsening side effects to your healthcare provider promptly.
• Keep a record of your symptoms and any changes you notice while using Mesbro.
• Inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Meningitis – Vaccination (NHS UK) [Accessed 13 Jun. 2024] (online) Available at:
• Mesna Injection (Health Professionals SmPC) Available at:
• Mesna oral/injection (Drugs.com) [Accessed 24 Jun. 2024] (online) Available at:
• mesna tablet (RX) [Accessed 9 Jun. 2024] (online) Available at:
• Mesna (MedlinePlus) [Accessed 5 Jun. 2024] (online) Available at:
• Schoenike SE, Dana WJ. Ifosfamide and mesna. Clin Pharm. 1990 Mar;9(3):179-91. [Accessed 19 Jun. 2024] Available at: